Paratek Pharmaceuticals (PRTK) PT Raised to $11 at Wedbush
Tweet
Share
E-mail
Get Alerts PRTK Hot Sheet
Price: $2.23 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Wedbush analyst Robert Driscoll raised the price target on Paratek Pharmaceuticals (NASDAQ: PRTK) to $11.00 (from $9.00) while maintaining a Outperform rating after the company has won a government contract to develop and stockpile Nuzyra (omadacycline) for the treatment of pulmonary anthrax.
- BARDA contract could be worth up to $285M over the next 5 years
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
- BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
